Physician profile
Daniel S Carter
NPI 1053774893
$585.33
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $227.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $200.25 | 2021-2022 | |
| Smith+Nephew, INC. | $119.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $111.39 | 2021 | |
| Abbvie INC. | $111.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $15.60 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.